After taking this supplement combo for 12 weeks, overweight and obese people burn more fat and less sugar for energy, even after eating a fatty meal.
Scientific Claim
Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol reduces fasting and postprandial respiratory quotient in overweight and obese adults, indicating a shift toward greater fat utilization as a fuel source.
Original Statement
“EGCG+RES reduced fasting (P-time × treatment = 0.03) and postprandial respiratory quotient (P-time × treatment = 0.01) compared with placebo.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
RCT design supports causation, but abstract lacks details on calorimetry methodology or control for diet. 'Reduces' is appropriate but should be qualified as 'likely' due to limited data.
More Accurate Statement
“Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol likely reduces fasting and postprandial respiratory quotient in overweight and obese adults, indicating a shift toward greater fat utilization as a fuel source.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether EGCG+RES consistently lowers RQ across populations and whether this effect is dose- or duration-dependent.
Whether EGCG+RES consistently lowers RQ across populations and whether this effect is dose- or duration-dependent.
What This Would Prove
Whether EGCG+RES consistently lowers RQ across populations and whether this effect is dose- or duration-dependent.
Ideal Study Design
A meta-analysis of ≥5 RCTs (n≥100 per trial) in overweight/obese adults comparing EGCG+RES (282+80 mg/d) vs placebo for ≥8 weeks, with primary outcome: fasting and postprandial RQ measured by indirect calorimetry after standardized high-fat meal.
Limitation: Cannot determine biological mechanisms or long-term metabolic consequences.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of EGCG+RES on RQ under controlled dietary and activity conditions.
Causal effect of EGCG+RES on RQ under controlled dietary and activity conditions.
What This Would Prove
Causal effect of EGCG+RES on RQ under controlled dietary and activity conditions.
Ideal Study Design
A double-blind RCT with 120 overweight/obese adults (BMI 27–35, aged 30–60) randomized to EGCG+RES or placebo for 12 weeks, with RQ measured via whole-room indirect calorimetry after standardized HFMM, under controlled diet and activity, with fasting and 4-h postprandial sampling.
Limitation: Does not establish whether reduced RQ leads to fat loss or improved metabolic health.
Prospective Cohort StudyLevel 2bWhether lower RQ from EGCG+RES supplementation predicts future fat mass reduction or metabolic improvement.
Whether lower RQ from EGCG+RES supplementation predicts future fat mass reduction or metabolic improvement.
What This Would Prove
Whether lower RQ from EGCG+RES supplementation predicts future fat mass reduction or metabolic improvement.
Ideal Study Design
A 2-year prospective cohort of 300 obese adults taking EGCG+RES (282+80 mg/d) or not, with quarterly RQ measurements and annual DEXA scans for fat mass, adjusting for diet, exercise, and medication use.
Limitation: Cannot prove causation due to potential confounding by self-selection and lifestyle.
Animal Model StudyLevel 4Mechanistic link between EGCG+RES, mitochondrial function, and substrate utilization in adipose and muscle tissue.
Mechanistic link between EGCG+RES, mitochondrial function, and substrate utilization in adipose and muscle tissue.
What This Would Prove
Mechanistic link between EGCG+RES, mitochondrial function, and substrate utilization in adipose and muscle tissue.
Ideal Study Design
A study in high-fat diet-fed rats (n=40/group) treated with EGCG+RES (equivalent human dose) for 12 weeks, measuring RQ via indirect calorimetry, muscle fatty acid oxidation rates, and expression of CPT1 and PPARα in muscle and liver.
Limitation: Rat metabolism differs from humans; cannot predict clinical outcomes.
Evidence from Studies
Supporting (1)
This study gave overweight people the same supplements mentioned in the claim for 12 weeks and found their bodies burned more fat instead of carbs, shown by a drop in a measurement called respiratory quotient — exactly what the claim says.